Biohaven Ltd. (BHVN) Dividend History

Biohaven Ltd. is a biopharmaceutical company focused on developing and commercializing innovative medicines for neurological and neuropsychiatric disorders. Known for its research in neuroscience, it has developed treatments targeting conditions such as migraines, neurodegenerative diseases, and other CNS disorders. The company emphasizes scientific innovation and the advancement of therapies to improve patient outcomes.

215 Church Street, New Haven, CT, 06510
Phone: 203-404-0410
Website: https://www.biohavenpharma.com

Dividend History

Biohaven Ltd. currently does not pay dividends

Company News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (BHVN) due to the FDA's extension of the PDUFA date for the troriluzole new drug application and the planned advisory committee meeting, which led to a 19.53% drop in the company's stock price.

GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (BHVN) due to the FDA's extension of the PDUFA date for the troriluzole new drug application and the planned advisory committee meeting, which caused a 19.53% drop in the company's stock price.

GlobeNewswire Inc.
Why Biohaven Stock Dove by Nearly 20% on Thursday

Biohaven's stock price dropped 19% after the FDA extended the review period for the company's promising pipeline drug troriluzole, which targets a rare brain disorder. The delay is disappointing, but the ultimate fate of the drug depends on the FDA's future actions.

The Motley Fool
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités

Merus reported positive interim data from its Phase II trial of petosemtamab in combination with pembrolizumab for first-line treatment of recurrent/metastatic HNSCC expressing PD-L1. The company also provided updates on its ongoing Phase III trials for petosemtamab and its collaboration programs.

GlobeNewswire Inc.

Featured Companies: GILD INCY LLY MRUS
Why Biohaven Stock Plummeted by More Than 15% Today

Biohaven, a clinical-stage biotech company, withdrew its application for a drug candidate in Europe, leading to a significant drop in its stock price. The European Medicines Agency cited several issues that mitigated against approval, and Biohaven plans to generate additional data to support a new application.

The Motley Fool

Featured Companies: RXRX

Dividend data last updated 06/07/2025 15:24:23 UTC